Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in OncologyUma Prabhakar, David C. Blakey, Simon T. Barry et al.|Cancer Research|2013Cited by 1.5k
Challenges and strategies in anti-cancer nanomedicine development: An industry perspectiveJennifer I. Hare, Simon T. Barry|Advanced Drug Delivery Reviews|2016Cited by 1.1k
Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR FamilySandra R. Brave, Simon T. Barry|Molecular Cancer Therapeutics|2011Cited by 88
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activityLarissa S. Carnevalli, Simon T. Barry|Journal for ImmunoTherapy of Cancer|2018Cited by 87
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Simon T. Barry|npj Breast Cancer|2023Cited by 16